|
gptkbp:instance_of
|
gptkb:immunotherapy
|
|
gptkbp:approves
|
gptkb:1987
gptkb:FDA
|
|
gptkbp:atccode
|
J05 AF01
|
|
gptkbp:availability
|
gptkb:brand
generic
|
|
gptkbp:brand
|
gptkb:Retrovir
|
|
gptkbp:can_be_combined_with
|
gptkb:abacavir
gptkb:lamivudine
gptkb:tenofovir
|
|
gptkbp:casnumber
|
30516-87-1
|
|
gptkbp:chemical_formula
|
C10 H13 N5 O4 S
|
|
gptkbp:clinical_trial
|
HIV treatment studies
|
|
gptkbp:composed_by
|
gptkb:chemical_compound
|
|
gptkbp:contraindication
|
hypersensitivity
severe liver disease
|
|
gptkbp:developed_by
|
gptkb:Burroughs_Wellcome
|
|
gptkbp:discovery
|
gptkb:Dr._Jerome_Horwitz
|
|
gptkbp:discovery_year
|
gptkb:1964
|
|
gptkbp:drug_interactions
|
gptkb:ribavirin
ganciclovir
methadone
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:formulation
|
gptkb:tablet
gptkb:Sugar
injection
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
zidovudine
|
|
gptkbp:lifespan
|
1 hour
|
|
gptkbp:marketed_as
|
gptkb:AZT
|
|
gptkbp:mechanism_of_action
|
reverse transcriptase inhibitor
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:name
|
Essential Medicines
|
|
gptkbp:provides_guidance_on
|
WHO guidelines
CDC guidelines
|
|
gptkbp:research
|
HIV prevention
mother-to-child transmission prevention
|
|
gptkbp:route_of_administration
|
oral
intravenous
|
|
gptkbp:side_effect
|
gptkb:muscular_dystrophy
gptkb:anemia
gptkb:lipodystrophy
fatigue
headache
nausea
lactic acidosis
peripheral neuropathy
|
|
gptkbp:used_for
|
treatment of HIV
|
|
gptkbp:bfsParent
|
gptkb:azidothymidine_(AZT)
gptkb:Ribavirin
gptkb:AZT
|
|
gptkbp:bfsLayer
|
5
|